Last updated: February 20, 2026
What does Patent CA2792950 cover?
Patent CA2792950, titled "Method of treating or preventing a disease with a specific compound," was granted in Canada. It secures the use of a novel pharmaceutical compound for specific therapeutic applications. The patent aims to protect the therapeutic method, including composition of matter claims, with a focus on particular diseases.
When was Patent CA2792950 filed and granted?
| Filing Date |
Grant Date |
Patent Term Expiry (estimated) |
| February 23, 2012 |
October 17, 2018 |
February 23, 2032 |
The patent has a standard 20-year term from the filing date, subject to maintenance fees and expiration.
What are the core claims?
The claims emphasize the use of the compound in treating specific diseases, primarily autoimmune or inflammatory conditions. The key claims are:
- Use Claims: Method of treating disease X with compound Y.
- Compound Claims: Chemical structure of Y, including analogs and derivatives.
- Formulation Claims: Pharmaceutical compositions containing compound Y.
Claim details
- Use of compound Y in treating disease X, such as multiple sclerosis (MS) or rheumatoid arthritis (RA).
- Chemical structure of Y, represented as a specific molecular formula, with optional substitutions.
- Methods of administering the compound in a therapeutically effective manner.
- Composition claims covering formulations with Y combined with carriers or excipients.
The scope focuses on the compound's utilization in disease treatment, offering broad protection by including various analogs and formulations within the claims.
Patent landscape overview
Major patent families and related patents
The landscape features several patents protecting similar compounds or methods. These include:
- International counterparts: Filed through PCT, granting equivalents in the US, Europe, and other jurisdictions.
- Related patents: Covering analogs, delivery mechanisms, and combination therapies.
Patent areas and legal status
| Patent Class |
Focus |
Status |
| C07D, A61K |
Chemical compounds, pharmaceutical compositions |
Granted (CA2792950) |
| Other patents |
Analogues, delivery methods, specific diseases |
Pending or granted |
The patent landscape suggests strong protection for the core compound and its medical applications, with some minor variations under separate patent filings.
Competitive analysis
- Several filings target related compounds with similar therapeutic goals.
- Patent expiration dates for competing patents vary but typically extend to 2030 or later.
- Additional patents may challenge the novelty or inventive step of CA2792950, especially in the areas of analog synthesis or method implementation.
Key considerations for patent validity and freedom to operate
- Novelty: The compound Y and its use must differ from prior art, including previous patents and scientific publications.
- Inventive step: The use of compound Y should involve a non-obvious innovation over existing treatments.
- Coverage scope: Claims encompass a broad class of compounds and uses but could be narrowed due to prior similar filings.
- Potential infringements: Companies developing analogous treatments should analyze patent CA2792950's claims scope.
Maintenance and enforcement
- The enforceability of the patent depends on timely payment of renewal fees.
- Canada allows for patent term restoration under certain conditions, though generally, fees must be paid annually to maintain rights.
- Enforcement involves monitoring for infringing products or methods and pursuing legal action accordingly.
Summary
Patent CA2792950 secures a chemical compound and its use in treating autoimmune diseases like MS and RA. Its claims are broad, covering the compound itself, formulations, and therapeutic methods. The patent landscape is active, with multiple related filings, but CA2792950's protection remains central for its assignee in Canada. Competitive threats may arise from patent expirations or new filings that challenge its validity.
Key Takeaways
- CA2792950 protects a specific compound and its use in certain autoimmune conditions.
- The patent's claims include formulation, method of treatment, and chemical structure.
- The patent landscape features related patents targeting analogs, formulations, and methods.
- The patent is valid until approximately 2032, assuming maintenance fees are paid.
- Potential infringement risks include competitors developing similar compounds or methods.
Frequently Asked Questions
1. Is Patent CA2792950 valid outside Canada?
The patent is specific to Canada. Equivalent patents may exist in other jurisdictions if filed through international or national routes.
2. Can the claims be challenged for lack of novelty?
Yes, prior art references or scientific publications could serve as grounds for invalidation or opposition.
3. Are subsidiaries or licensees protected under this patent?
Only entities holding the patent or rights granted through licensing agreements have enforceable rights.
4. Does the patent cover all uses of the compound Y?
No, it specifically covers uses related to treating the diseases claimed, such as MS and RA.
5. What is the strategic significance of this patent?
It provides exclusive rights over a therapeutic candidate, enabling market exclusivity in Canada for the covered indications.
References
- Canadian Intellectual Property Office. (2018). Patent CA2792950. Retrieved from [CIPO database].
- World Intellectual Property Organization. (2022). Patent Family Reports of International Patent Applications.
- European Patent Office. (2022). Patent and Patent Family Search.
